Transdermal Delivery Systems: A Medical Rationale

Cleary, Gary W.

doi:10.1007/978-1-4899-1262-6_2

Cited by 39 publications

(23 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This problem reportedly has been overcome with the use of Dot Matrix TM technology (Noven Pharmaceuticals) to achieve high concentrations of drug (or more than one drug) within adhesive patches of a realistic area for application, e.g., Vivelle-Dot R (Novartis AG). For a more detailed review on patches, the reader is referred to the following authors: Cleary (1991), Cleary (1993), Hadgraft (1996), Ghosh Pfister, andYum (1997), and Venkatraman and Gale (1998).…”

Section: Passive Methodsmentioning

confidence: 99%

Dermal and Transdermal Drug Delivery Systems: Current and Future Prospects

et al. 2006

View full text Add to dashboard Cite

Section: Passive Methodsmentioning

confidence: 99%

Dermal and Transdermal Drug Delivery Systems: Current and Future Prospects

et al. 2006

View full text Add to dashboard Cite

“…Iontophoresis, of course, has been known and studied for over 100 years and it remains, to all intents and purposes, the only 'physical' transdermal technology to have received regulatory approval and for which commercial products have been marketed 3 . This mature technology is one for which an excellent mechanistic understanding has been defined and a more than reasonable safety profile exists.…”

Section: Future Perspectives For Transdermal Drug Deliverymentioning

confidence: 99%

“…It was further argued, not unreasonably, that achieving these aims would lower variability, both within and between patients and substantially improve, as a result, compliance and adherence with drug use [1][2][3].…”

Section: Introductionmentioning

confidence: 99%

“…Such compounds typically have very low (or even non-existent, in some cases) oral bioavailability, particularly inconvenient dosing regimens, and significant incidences of adverse effects, often the result of the high levels of metabolite(s) formed on their first passage through the liver. In contrast, by administering such drugs transdermally, the classic first-pass effect is avoided and these major drawbacks are circumvented [1][2][3][4].…”

Section: Introductionmentioning

confidence: 99%

“…Should either skin permeability or pharmacological potency be insufficient, then TDD becomes impossible without an impracticably large patch [1,3]. Testosterone, for example, has walked this fine line with the result that the present approach of choice to deliver this compound is a gel formulation, which can be applied over a larger surface area 2 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Transdermal drug delivery: 30 + years of war and still fighting!

Wiedersberg

Guy

2014

Journal of Controlled Release

246

152

View full text Add to dashboard Cite

By any measure, transdermal drug delivery (TDD) is a successful controlled release technology. Over the last 30+ years, a steady flux of transdermal products have received regulatory approval and reached the market. For the right compounds, TDD is an effective and preferred route of administration; for others, delivery across the skin makes no sense at all. Currently, the "rules" that govern (passive) TDD feasibility are clearly understood, and research activity is focused on novel approaches that strive to subvert skin's excellent barrier function, and broaden the range of active species amenable to percutaneous administration.

show abstract

Formulation and in vitro evaluation of transdermal delivery of zidovudine—An anti‐HIV drug

Mundargi¹,

Babu²,

Rangaswamy³

et al. 2010

J of Applied Polymer Sci

View full text Add to dashboard Cite

This study was designed to develop matrix type of transdermal-controlled delivery system for zidovudine using Eudragit L100 by varying the amounts of drug in addition to polyethylene glycol as a plasticizer and Tween 80V R as a penetration enhancer. Transparent smooth and flexible films were characterized for weight, thickness uniformity, and drug content. Drug interactions with the polymer films were studied by differential scanning calorimetry, whereas X-ray diffraction was used to understand the drug polymorphism in the films. The in vitro drug release experiments were performed in phosphate buffer using the Keshary-Chien diffusion cell. Variations of drug release profiles were analyzed using the Ritger and Peppas empirical equation to describe the type of release mechanism. The exponent n values of the equation varied over the wide range of 0.75-2.23, suggesting non-Fickian to super Case-II type of diffusion transport. Statistical analyses of release data performed by the analysis of variance (ANOVA) method indicated significant differences within experimental measurements.

show abstract

Transdermal Delivery Systems: A Medical Rationale

Cited by 39 publications

References 61 publications

Dermal and Transdermal Drug Delivery Systems: Current and Future Prospects

Dermal and Transdermal Drug Delivery Systems: Current and Future Prospects

Transdermal drug delivery: 30 + years of war and still fighting!

Formulation and in vitro evaluation of transdermal delivery of zidovudine—An anti‐HIV drug

Contact Info

Product

Resources

About